CN107383167B

CN107383167B - Antioxidant active peptide and application thereof

Info

Publication number: CN107383167B
Application number: CN201710666963.9A
Authority: CN
Inventors: 罗海哨; 余作取
Original assignee: Wenzhou Qianrui Biotechnology Co ltd
Current assignee: Wenzhou Qianrui Biotechnology Co ltd
Priority date: 2017-08-07
Filing date: 2017-08-07
Publication date: 2021-02-09
Anticipated expiration: 2037-08-07
Also published as: CN107383167A

Abstract

The invention relates to the field of cosmetics, and particularly relates to an antioxidant active peptide and application thereof. The peptide of the invention can improve the skin luster and remove dark yellow. Specifically, the invention provides peptides of peptide.02 and application thereof in preparing a composition for improving skin luster and removing dark yellow. The peptides and compositions of the present invention can improve skin radiance and remove dark yellowness. In particular, the peptides and compositions of the invention are suitable for use in cosmetic form.

Description

Antioxidant active peptide and application thereof

Technical Field

The invention relates to the field of cosmetics, and particularly relates to an antioxidant active peptide and application thereof.

Background

Oxidation is the biggest threat of skin aging, the skin can be flooded by free radicals due to unhealthy diet, solarization, pressure, environmental pollution and the like, and thus, the oxidation phenomena such as dark complexion, water shortage and the like are generated. These are the "main culprits" for the body to become oxidized. Therefore, from the health aspect or the skin care aspect, people need to pay attention to oxidation resistance in daily life.

The antioxidant substances of the human body are synthesized by themselves and are also supplied by food. Enzymatic and non-enzymatic antioxidants play a crucial role in protecting peroxidative damage due to exercise. The supplement of antioxidant substances is beneficial to the exercise body to reduce the generation of free radicals or accelerate the elimination of the free radicals so as to resist the side effects of the free radicals, thereby being beneficial to the health of common people and athletes, possibly delaying the occurrence of exercise-induced fatigue and accelerating the physical recovery. The antioxidant is better for the physically active people of old age than for the younger people.

The polypeptide is a compound with a molecular structure between amino acid and protein, so that the protein has certain physiological function. In human life activities, peptides are digested and absorbed better than free amino acids in vivo, and there is a different in vivo delivery system from amino acids. Some short peptides can provide nutrient substances necessary for growth and development of human body, and at the same time can prevent and cure diseases and regulate human body function, and these bioactive polypeptides are called bioactive peptides. Researches show that polypeptides from different sources have antioxidant capacity, and polypeptides obtained by hydrolyzing casein, soybean protein, bovine serum albumin, ovalbumin, oilseed protein, gliadin, zein and the like have certain antioxidant capacity.

CN201410079022.1 discloses an antioxidant polypeptide and a preparation method thereof, the method takes chlorella protein as raw material, and the specific antioxidant polypeptide is obtained by enzymolysis of acid protease, separation and purification. The peptide provided by the patent application eliminates the defects of natural antioxidants and the worry of the public about artificially synthesized antioxidants, and lays a foundation for developing antioxidant polypeptides based on food sources and exploring the wide application of the antioxidant polypeptides in foods and medicines.

Chinese patent CN201210019564 discloses an antioxidant composition, which comprises: an active powder selected from one or more of vitamin C, vitamin C derivatives, arbutin derivatives, and oligopeptide powder (such as glutathione and carnosine); a solvent selected from one or more of polyhydric alcohols, ethoxy glycol, and ethoxy glycol derivatives; and a selective additive, which is selected from one or more of substances with oxidation resistance, substances with free radical capturing, substances with metal chelating property and substances with UV sun-screening property; by the above composition, the active ingredients in the active powder are mixed with the solvent first, so as to isolate the penetration of moisture and effectively reduce the oxidation and yellowing; and the user can apply the antioxidant composition on the skin to achieve the effect of improving skin spots and darkness.

CN2015100671513 discloses an emulsion combining antioxidant active oligopeptide and a sunscreen agent, wherein the cosmetic contains 0.1-20% of bioactive peptide and 1-30% of sunscreen agent. The bioactive peptide is dipeptide and tripeptide with antioxidant activity; wherein the dipeptide is carnosine; the tripeptide is selected from one or more of glutathione, synthetic tripeptide phenylalanine-lysine-leucine and collagen tripeptide. The invention combines dipeptide and tripeptide with antioxidant activity as bioactive peptide for eliminating free radicals in vivo, and effectively combines the bioactive peptide with a non-bioactive sunscreen agent, thereby protecting skin from ultraviolet radiation and eliminating damage of free radicals to skin.

CN201210407446 discloses an antioxidant activity synthetic peptide and application thereof, and experiments prove that 3 synthesized polypeptides have antioxidant activity, and the antioxidant peptide has the characteristics of small molecular weight, high activity, easiness in artificial synthesis, low cost and the like, so that the antioxidant activity synthetic peptide can be widely applied to large-scale production in industries of foods, cosmetics, medicines and the like.

However, no antioxidant peptides are currently on the market which are satisfactory to consumers, in particular peptides which can be applied to cosmetics and produce a beneficial effect.

Disclosure of Invention

In order to solve the above problems, the present inventors have diligently made efforts to develop pentapeptides having antioxidant activity and find that they have good applications in cosmetics.

Accordingly, it is an object of the present invention to provide a peptide having an antioxidant activity, which has the sequence structure of Leu-Val-Tyr-Trp-Gly (peptide.02).

The invention also provides a cosmetic composition for promoting skin to have luster and eliminating dark yellow, which comprises the sequence with PEPTIDE.02.

The peptide has antioxidant activity, and further has the effects of promoting skin luster and eliminating dark yellow. Therefore, the invention provides the application of the peptide of PEPTIDE.02 in preparing a composition for promoting the skin to have luster and eliminating dark yellow.

The peptide and the composition have antioxidant activity, and further have the effects of promoting skin luster and eliminating dark yellow. In particular, the peptides and compositions of the invention are suitable for use in cosmetic form.

Detailed Description

The peptide of the present invention can be synthesized by a synthetic method using organic chemistry, and can be synthesized by a general method such as a solid phase method (Boc method, Fmoc method) or a liquid phase method, for example, automatically using a peptide synthesizer. The reaction conditions for peptide synthesis and the like may be arbitrarily set based on the technical common knowledge of those skilled in the art, such as the selected synthesis method and appropriate reaction conditions. Methods for purifying chemically synthesized peptides are also well known to those skilled in the art. The peptide obtained by the solid phase synthesis method can be obtained by purifying by high pressure liquid chromatography and freeze drying.

In the present specification, when referring to these peptides, "peptides" include their salts except where specifically indicated or where clearly excluded from the text. Such salts include sodium salts, potassium salts, and the like which may exist under physiological conditions.

The content of the peptide of the present invention in the final product is 0.0001 to 50% by mass, preferably 0.005 to 10% by mass, and more preferably 0.005 to 0.010% by mass, depending on the form of the composition of the present invention to be added or the form of the product.

The peptides of the invention are provided in a cosmetically acceptable carrier. The carrier may be hydrophobic or hydrophilic. Suitable hydrophobic carriers include, for example, waxy nonionic materials commonly used in cosmetics, such as esters and ethers of fatty alcohols and fatty acids, with carbon chain lengths of C4 to C22, preferably C8 to C18, most preferably C12 to C18.

Examples of fatty hydrophobic carriers include isopropyl myristate, isopropyl palmitate, octyl palmitate, isopropyl lanolate, acetylated lanolin alcohol, benzoate esters of C12-C15 alcohols, cetyl octanoate, cetyl palmitate, myristyl myristate, myristyl lactate, cetyl acetate, propylene glycol dicaprylate/decanoate, decyl oleate, acetylated lanolin, heptanoic stearate, diisostearate malate, octyl hydroxystearate, isopropyl isostearate, and the like.

Suitable hydrophilic carrier solutions may be, for example, glycols and alkoxylated glycols commonly used in cosmetics, including ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, and the like.

The wound healing promoting composition may be formulated as a nutritional liquid, serum, whitening cream, lotion, serum, spray, stick, and other forms known to those skilled in the art. Serum is the currently preferred product form.

In a cosmetically acceptable carrier, the concentration of the peptide may range from 1. mu.M to 200. mu.M, preferably from 10ppb to 150. mu.M, more preferably from 20. mu.M to 100. mu.M, most preferably from 36. mu.M to 50. mu.M.

Wound healing promoting compositions typically comprise the above-described carrier solutions at a level of from about 0.01% to about 90% by weight, preferably from about 0.1% to about 50% by weight, more preferably from about 0.1% to about 20% by weight, and most preferably from about 1% to about 10% by weight.

Examples of the antioxidant include butylhydroxyanisole, dibutylhydroxytoluene, sodium hydrogensulfite, erythorbic acid and salts thereof, glutathione peroxidase, glutathione-S-transferase, catalase, superoxide dismutase, thioredoxin, taurine, thiotaurine, hypotaurine, and vitamin E. Among them, vitamin E and catalase are preferable. These antioxidants may be used in combination of 1 or more than 2, and are preferably a combination of glutathione and vitamin E. When the antioxidant is added to the composition for external application to the skin (for example, cream) of the present invention, the addition ratio thereof is not particularly limited, but is usually 0.001 to 6% by weight, preferably 0.01 to 3% by weight, and more preferably 0.2 to 2% by weight, based on the total amount of the composition for external application to the skin.

Examples of the humectant include amino acids such as alanine, serine, leucine, isoleucine, threonine, glycine, proline, hydroxyproline, aspartic acid, arginine, and theanine, and derivatives thereof; polyhydric alcohols such as ethylene glycol, 1, 3-propanediol, 1, 3-butanediol, diethylene glycol, triethylene glycol, tetraethylene glycol, dipropylene glycol, diglycerin, and polyethylene glycol; glycol ethers such as ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, ethylene glycol monopropyl ether, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, diethylene glycol monopropyl ether, diethylene glycol monobutyl ether, propylene glycol monoethyl ether, propylene glycol monopropyl ether, dipropylene glycol monoethyl ether, and dipropylene glycol monopropyl ether; sugar alcohols such as mannitol, sorbitol, erythritol, xylitol, and trehalose; phospholipids such as lecithin and hydrogenated lecithin; mucopolysaccharides such as sodium hyaluronate, sodium acetylhyaluronate, heparin analogues, sodium chondroitin sulfate, etc.; high molecular compounds such as collagen, elastin, keratin, chitin, chitosan, gelatin, polyglutamic acid, etc.; sodium lactate, sodium pyrrolidone carboxylate, etc.; chamomile extract, aloe vera extract, witch hazel extract, rosemary extract, thyme extract, tea extract, perilla extract, and other plant extracts. Among them, glycine, 1, 3-propanediol, dipropylene glycol, diglycerin, diethylene glycol monoethyl ether, sodium hyaluronate, sodium acetylhyaluronate, sodium pyrrolidone carboxylate, and polyglutamic acid are preferable. These moisturizers may be used in 1 kind or in combination of 2 or more kinds, and 1, 3-propanediol and sodium hyaluronate are preferred. When the moisturizing agent is added to the composition for external application to the skin (e.g., cream) of the present invention, the addition ratio is not particularly limited, but is usually 0.001 to 40% by weight, preferably 0.1 to 30% by weight, and more preferably 5 to 20% by weight, based on the total amount of the composition for external application to the skin (e.g., cream).

The vegetable oil is selected from rose hip oil, sweet almond oil, rose hip oil, jojoba oil, wheat germ oil, carrot oil, avocado oil, castor oil, avocado oil, coconut oil, palm oil, cocoa butter, palm kernel oil, soybean oil, rice bran oil, aloe oil, veronica officinalis, chenopodium album butter, shea butter, peanut oil, corn oil, macadamia nut oil, Chinese chestnut oil, seabuckthorn oil, linseed oil, passion flower oil, calendula, mango kernel oil and rose hip oil, and is preferably one or a combination of two or more of sweet almond oil, jojoba oil and rose hip oil. Preferably, the vegetable oil in the composition of the invention is rose hip oil. When the vegetable oil is added to the composition for external application to skin (e.g., cream) of the present invention, the addition ratio is not particularly limited, but is usually 0.001 to 10% by weight, preferably 0.5 to 8% by weight, and more preferably 1.0 to 8.0% by weight, based on the total amount of the composition for external application to skin (e.g., cream).

The base is selected from vegetable oils, hydrogenated vegetable oils, beeswax, insect wax, spermaceti wax, paraffin wax, liquid paraffin, vaseline, silicone, polyacrylic acid, cellulose derivatives, and the like, and may be one or a combination of two or more selected from them. Preferably, the base in the composition of the present invention is one or a combination of two or more selected from the group consisting of liquid paraffin and vaseline. When a base is added to the composition for external application to skin (e.g., cream) of the present invention, the addition ratio is not particularly limited, but is usually 0.001 to 10% by weight, preferably 0.5 to 8% by weight, and more preferably 1.0 to 8.0% by weight, based on the total amount of the composition for external application to skin (e.g., cream).

As preservative, it is selected from benzyl alcohol, phenethyl alcohol, phenoxyethanol and lauroyl arginine ethyl ester, preferably lauroyl arginine ethyl ester. When the antiseptic is added to the composition for external application to skin (e.g., cream) of the present invention, the addition ratio thereof is not particularly limited, but is usually 0.001 to 5% by weight, preferably 0.1 to 5% by weight, and more preferably 0.2 to 3% by weight, based on the total amount of the composition for external application to skin (e.g., cream).

Preferably, the cream of the invention comprises 0.0005-0.001 wt% of peptide PEPTIDE.02, and 0.5-2.5 wt% of taurine, 2.0-4.0 wt% of ethylene glycol, 4.0-6.0 wt% of tea extract, 2.0-4.0 wt% of rose hip oil, 2.0-4.0 wt% of liquid paraffin, 8.0-12.0 wt% of vaseline, and a proper amount of lauroyl arginine ethyl ester.

Preferably, the cream of the invention comprises 0.001 wt% of PEPTIDE.02 peptide, and 0.5-2.5 wt% of taurine, 2.0-4.0 wt% of ethylene glycol, 4.0-6.0 wt% of tea extract, 2.0-4.0 wt% of rose hip oil, 2.0-4.0 wt% of liquid paraffin, 8.0-12.0 wt% of vaseline and a proper amount of lauroyl arginine ethyl ester.

Preferably, the composition according to the invention comprises, in% by weight:

0.0005-0.001 wt% of PEPTIDE.02 peptide, and proper amount of glutathione 0.5-2.5, 1.3 propylene glycol 2.0-4.0, resveratrol 4.0-6.0, phytosterol oleate 2.0-4.0, fullerene 2.0-4.0, soybean lecithin 2.0-4.0, carbomer 8.0-12.0, perilla extract 0.01-1.2, flos Rosae Rugosae extract 0.01-1.0, herba Dendrobii extract 0.01-1.0, herba Portulacae extract 0.01-1.5, dextran 0.01-1.5, hyaluronic acid 0.01-4.0, nicotinamide 0.1-0.5 and lauroyl arginine ethyl ester.

More preferably, the composition according to the invention comprises, in% by weight:

0.001 wt% of PEPTIDE.02 peptide, and 0.5-2.5 wt% of glutathione, 2.0-4.0 wt% of 1.3 propylene glycol, 4.0-6.0 wt% of resveratrol, 2.0-4.0 wt% of phytosterol oleate, 2.0-4.0 wt% of fullerene, 2.0-4.0 wt% of soybean lecithin, 8.0-12.0 wt% of carbomer, 0.01-0.80 wt% of perilla extract, 0.01-0.4 wt% of rose extract, 0.01-0.5 wt% of dendrobium officinale extract, 0.01-0.6 wt% of purslane extract, 0.01-0.8 wt% of glucan, 0.01-2.0 wt% of hyaluronic acid, 0.1-0.5 wt% of nicotinamide and a proper amount of lauroyl arginine ethyl ester.

Most preferably, the composition of the invention comprises in weight%: 0.0005 wt% of PEPTIDE.02 peptide, and proper amount of glutathione of 0.5-2.5, 1.3 propylene glycol of 2.0-4.0, resveratrol of 4.0-6.0, phytosterol oleate of 2.0-4.0, fullerene of 2.0-4.0, soybean lecithin of 2.0-4.0, carbomer of 8.0-12.0, perilla extract of 0.1-0.5, rose extract of 0.1-0.2, dendrobium officinale extract of 0.1-0.2, purslane extract of 0.1-0.4, dextran of 0.1-0.5, hyaluronic acid of 0.1-1.0, nicotinamide of 0.1-0.5 and lauroyl arginine ethyl ester.

The instructions contained in the wound-healing promoting product of the present invention relating to the wound-healing promoting product may contain the following: effects and efficacies (e.g. promotion of wound healing), methods of application (e.g. even application to the skin, e.g. face and neck), and possible side effects, etc.

The terms and expressions which have been employed herein are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.

For a more clear illustration of the invention, reference is now made in detail to the following examples, which are intended to be purely exemplary of the invention and are not to be interpreted as limiting the application.

Examples

The following examples are intended to illustrate the invention in a non-limiting manner.

EXAMPLE 1 solid phase Synthesis of peptides

Selecting high molecular resin, according to the characteristics of an amino acid sequence Leu-Val-Tyr-Trp-Gly, firstly connecting the carboxyl of Leu with the resin in a covalent bond mode, then carrying out a shrinkage reaction on the amino of Leu and the carboxyl of Val, adding Tyr, reacting the amino of Val and the carboxyl of Tyr, sequentially adding amino acid from right to left, adding the last Gly amino acid, and then cutting off the resin to obtain the target synthetic pentapeptide. The final product was obtained by HPLC purification using a PhenomenexC 18(4.6 x 250mm) column at a flow rate of 1.0 mL/min. Eluting with two channels, wherein solvent A is water containing 0.1% trifluoroacetic acid; solvent B-a solution containing 0.09% trifluoroacetic acid (80% acetonitrile + 20% water); the initial proportion of B in the elution gradient was 39%, and within 20min, the proportion of B rose to 49% at a detection wavelength of 220 nm. The synthetic pentapeptide solution was collected, snap-cooled with liquid nitrogen, and then lyophilized. The product with the purity of over 93 percent is obtained, and the structure is identified by ESI-MS.

EXAMPLE 2 ABTS free radical scavenging action of pentapeptide of PEPTIDE.02 synthesized

Preparing 7mmol/L ABTS with distilled water⁺The ABTS was separated from the solution and a 2.45mmol/L potassium persulfate solution (which had to be allowed to stand at room temperature for 16h before use)⁺Mixing with potassium persulfate solution at a volume ratio of 1: 1, and diluting the mixture with phosphate buffer solution (pH 7.4, 5 mmol/L) to light absorption value A before use₇₃₄Is 0.70 +/-0.02. 0.5mL of samples with different concentrations and 0.5mL of ABTS free radical solution were mixed and left for 10min, and then the absorbance was measured at 734 nm. The samples were replaced with deionized water and reduced glutathione as a blank control and a positive control, respectively. The ABTS free radical scavenging activity is calculated according to the following formula:

in the formula, A₀: blank control light absorption value; a. the_s: absorbance of sample set.

The pentapeptide of PEPTIDE.02 has stronger scavenging activity to ABTS free radicals, the free radical scavenging rate reaches 80% when the concentration is 2.5 mu g/mL, and the free radical scavenging rate of the pentapeptide of PEPTIDE.02 almost reaches 97% when the concentration is increased to 25.0 mu g/mL, and is far greater than the free radical scavenging rate of the positive control GSH with the same concentration.

EXAMPLE 3 pentapeptide of PEPTIDE.02 synthesized by ORAC method for determining antioxidant activity value of antioxidant peptide

The reaction was carried out in a 70mM potassium phosphate buffer (pH 7.5) environment based on ORAC reaction, and fluorescent agent FL was formulated as a high concentration stock solution with the buffer, dispensed in small volumes, and stored at 4 ℃. The necessary amount was taken out at the time of the experiment and diluted with the same 70mM potassium phosphate buffer solution to a final concentration of 70nM in the reaction system. AAPH with 70mM potassium phosphate buffer solution to the reaction system final concentration of 12mM use. And dissolving and diluting the standard antioxidant substance Trolox and a sample to be detected by using a buffer solution. AAPH and Trolox were used extemporaneously.

Specifically, the determination operation comprises the steps of respectively adding 20 mu L of 5 mu M polypeptide solution to be determined into each micropore of a 96-pore plate, adding 120 mu L of FL, presetting for 12min at 37 ℃, quickly adding 60 mu L of AAPH into each pore by using a multi-channel pipettor to start reaction, placing the micropore plate into a fluorescence analyzer, and continuously determining at 37 ℃ at excitation wavelength 485nm and emission wavelength 520nm, wherein the fluorescence intensity of each pore is determined every 1min, and the determination time is 2 h.

The ORAC experiment required setting of two controls, a FL fluorescence natural decay control without added free radical (-AAPH) and a free radical action control in the absence of antioxidant (+ AAPH). The antioxidant capacity of the sample is directly related to the delayed partial area of the fluorescence decay curve (NetAUC) under the action of free radicals. The difference between the area under the fluorescence decay curve under the action of the antioxidant and the area under the fluorescence decay curve under the action of free radicals in the absence of the antioxidant, namely the area Net AUC of the delayed part of the fluorescence extinction curve is the protection area of the antioxidant.

AUC＝1+(f1/f0+f2/f0+f3/f0+……+fn/f0)

Where f0 refers to the initial fluorescence reading; fn refers to the fluorescence reading at n min; net AUC ═ AUC antioxidant-AUC control.

The final results are expressed as micromolar concentration of Trolox required for equivalent antioxidant capacity per micromolar concentration of the polypeptide solution to be tested.

The result shows that the ORAC activity values of the PEPTIDE.02 antioxidant polypeptides are respectively 6.85 (mu mol Trolox/mu mol) and are obviously higher than that of the positive control VC and GSH under the same conditions (the ORAC activity values are respectively 0.96 and 1.41). The polypeptide has higher antioxidant activity.

Example 4: preparation of essence

Composition (I)	Content (wt%)
		The peptide of the present invention (peptide.02)	0.001
Glutathione	1.5
		1.3 propylene glycol	3.0
Resveratrol	5.0
		Phytosterol oleate	3.0
Fullerene	3.0
		Soybean lecithin	3.0
Carbomer	10.0
		Perilla extract	0.1
Rose extract	0.1
		Dendrobium officinale extract	0.1
Purslane extract	0.1
		Glucan	0.1
Hyaluronic acid	0.2
		Nicotinamide	0.1
Lauroyl arginine ethyl ester	0.5
		Purified water	Residual amount
Total of	100

Mixing fullerene, soybean lecithin, carbomer and phytosterol oleate, stirring uniformly, adding other components, stirring and preparing into essence.

Example 5: preparation of essence

Example 6: preparation of essence

Composition (I)	Content (wt%)
		The peptide of the present invention (peptide.02)	0.0005
Glutathione	0.5
		1.3 propylene glycol	4.0
Resveratrol	4.0
		Phytosterol oleate	2.0
Fullerene	4.0
		Soybean lecithin	4.0
Carbomer	8.0
		Perilla extract	0.2
Rose extract	0.15
		Dendrobium officinale extract	0.15
Purslane extract	0.2
		Glucan	0.3
Hyaluronic acid	1.0
		Nicotinamide	0.25
Lauroyl arginine ethyl ester	0.3
		Purified water	Residual amount
Total of	100

Example 7 verification of the Activity of the serum

Skin external compositions of the essences (for improving skin luster and removing dark yellow) were prepared according to the formulations shown in examples 4, 5 and 6, and the same products were commercially available as comparative examples. For each skin external composition, 10 women of 30 to 35 years old were allowed to evaluate the feeling of use when applying the preparation on the face according to the following criteria.

And 5, dividing: the skin surface has high glossiness and outstanding smooth effect;

and 4, dividing: the skin surface has general glossiness, and the smooth effect is visible;

and 3, dividing: no visible change;

and 2, dividing: the skin surface has a slightly rough feel, and has no whitening and smooth effect;

1 minute: the skin surface had a rough feel, no whitening and exhibited a smooth effect.

The average score of the above evaluation results was calculated, and the results showed that the average scores of examples 4, 5 and 6 were all 4.5 or more, and the average score of the control sample was 3.2. The effect of example 5 was most prominent with an average score of 4.9.

Although the present invention has been described in the above-mentioned embodiments, it is to be understood that the present invention may be further modified and changed without departing from the spirit of the present invention, and that such modifications and changes are within the scope of the present invention.

Sequence listing

<110> Winzhou Qianri Biotechnology Ltd

<120> antioxidant active peptide and use thereof

<130> SGYX1710

<160> 1

<170> PatentIn version 3.3

<210> 1

<211> 5

<212> PRT

<213> Artificial sequence

<220>

<223> peptides for increasing luster and decreasing dark peptides

<400> 1

Leu Val Tyr Trp Gly

1 5

Claims

1. Use of a peptide consisting of the amino acid sequence of Leu-Val-Tyr-Trp-Gly for the preparation of a composition for lightening the skin and removing dark yellows, wherein the composition is a cosmetic composition and further comprises glutathione, 1, 3-propanediol, resveratrol, phytosterol oleate, fullerene, soy lecithin, carbomer, perilla extract, rose extract, dendrobium officinale extract, purslane extract, dextran, hyaluronic acid, nicotinamide and ethyl lauroyl arginate.

2. Use according to claim 1, characterized in that said composition comprises, in weight%:

0.0005-0.001 wt% of a peptide consisting of an amino acid sequence of Leu-Val-Tyr-Trp-Gly, and 0.5-2.5 wt% of glutathione, 2.0-4.0 wt% of 1, 3-propanediol, 4.0-6.0 wt% of resveratrol, 2.0-4.0 wt% of phytosterol oleate, 2.0-4.0 wt% of fullerene, 2.0-4.0 wt% of soybean lecithin, 8.0-12.0 wt% of carbomer, 0.1-0.5 wt% of perilla extract, 0.1-0.2 wt% of rose extract, 0.1-0.2 wt% of Dendrobium officinale extract, 0.1-0.4 wt% of purslane extract, 0.1-0.5 wt% of glucan, 0.2-1.0.0, 0.1-0.0.5 wt% of hyaluronic acid, 0.1-0.5 wt% of nicotinamide and 0.1-0.5 wt% of lauroyl arginine ethyl ester.

3. Use according to claim 2, comprising in wt.%:

0.001 wt% of a peptide consisting of the amino acid sequence of Leu-Val-Tyr-Trp-Gly.

4. Use according to claim 2, comprising in wt.%:

0.0005 wt.% of a peptide consisting of the amino acid sequence of Leu-Val-Tyr-Trp-Gly.